チカグレロル
↑ “2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)”. European Heart Journal 37 (3): 267–315. (January 2016). doi:10.1093/eurheartj/ehv320. PMID 26320110.
↑ “2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Journal of the American College of Cardiology 64 (24): e139-e228. (December 2014). doi:10.1016/j.jacc.2014.09.017. PMID 25260718.
↑ “Brilinta (ticagrelor) Prescribing Information”. AstraZeneca (2019年). 2021年6月12日閲覧。
↑ “Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?”. Thrombosis and Haemostasis 108 (3): 412–4. (September 2012). doi:10.1160/TH12-04-0251. PMID 22836596.
↑ “Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study”. American Heart Journal 157 (4): 658–65. (April 2009). doi:10.1016/j.ahj.2008.08.031. PMID 19332192.
↑ “Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis”. Cardiovascular Revascularization Medicine 19 (6): 689–694. (September 2018). doi:10.1016/j.carrev.2018.01.
JACC. Basic to Translational Science 3 (4): 435–449. (August 2018). doi:10.1016/j.jacbts.2018.05.005. PMC 6115703. PMID 30175268. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115703/.
1 2 “ブリリンタ錠60mg/ブリリンタ錠90mg 添付文書”. www.info.pmda.go.jp. PMDA. 2021年6月12日閲覧。
↑ “Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor”. Clinical Pharmacology 5: 67–83. (April 2013). doi:10.2147/cpaa.s41859. PMC 3640601. PMID 23650452. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640601/.
↑ “Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial”. European Heart Journal 32 (23): 2933–44.
Journal of the American College of Cardiology 68 (10): 1082–115. (September 2016). doi:10.1016/j.jacc.2016.03.513. PMID 27036918.
↑ “Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack”. The New England Journal of Medicine 375 (1): 35–43. (July 2016). doi:10.1056/NEJMoa1603060. PMID 27160892.
↑ “Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA”. The New England Journal of Medicine 383 (3): 207–217. (July 2020). doi:10.1056/NEJMoa1916870. PMID 32668111.
1 2 “Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial”. The Lancet.